Literature DB >> 26256591

Carisoprodol - Effects on Human Performance and Behavior.

M M Robertson1, L J Marinetti2.   

Abstract

Carisoprodol, a commonly prescribed muscle relaxant, has adverse effects on human performance and is gaining recognition as a factor in driver impairment and accident causation. Carisoprodol is a centrally acting skeletal muscle relaxant indicated for the relief of musculoskeletal pain. Carisoprodol and its major metabolite meprobamate have central nervous system (CNS) sedating effects similar to benzodiazepines or alcohol. Following the ingestion of carisoprodol or meprobamate symptoms such as drowsiness, confusion, poor balance, and coordination are well documented in drivers, all of which are detrimental to human performance and driving ability. Although identified as a drug capable of producing decreased human performance, the full extent of carisoprodol and meprobamate's involvement in motor vehicle accidents and effect on driving skills may not be fully appreciated. This is due in part to the common co-administration of other CNS depressants, hypnotics, or narcotic drugs and the lack of routine testing for carisoprodol and meprobamate in the human performance toxicology laboratory.
Copyright © 2003 Central Police University.

Entities:  

Keywords:  Behavior; carisoprodol; driving; human performance; impairment; meprobamate

Year:  2003        PMID: 26256591

Source DB:  PubMed          Journal:  Forensic Sci Rev        ISSN: 1042-7201


  5 in total

1.  Characterizing the subjective and psychomotor effects of carisoprodol in healthy volunteers.

Authors:  James P Zacny; Judith A Paice; Dennis W Coalson
Journal:  Pharmacol Biochem Behav       Date:  2011-08-23       Impact factor: 3.533

2.  Assessment of subunit-dependent direct gating and allosteric modulatory effects of carisoprodol at GABA(A) receptors.

Authors:  Manoj Kumar; Lorie A González; Glenn H Dillon
Journal:  Neuropharmacology       Date:  2015-04-18       Impact factor: 5.250

3.  The CYP2C19 genotype and the use of oral contraceptives influence the pharmacokinetics of carisoprodol in healthy human subjects.

Authors:  Jørgen G Bramness; Svetlana Skurtveit; Margaretha Gulliksen; Harald Breilid; Vidar M Steen; Jørg Mørland
Journal:  Eur J Clin Pharmacol       Date:  2005-07-15       Impact factor: 2.953

4.  Abuse Potential of Soma: the GABA(A) Receptor as a Target.

Authors:  Lorie A Gonzalez; Michael B Gatch; Michael J Forster; Glenn H Dillon
Journal:  Mol Cell Pharmacol       Date:  2009-01-01

5.  Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies.

Authors:  Lorie A Gonzalez; Michael B Gatch; Cynthia M Taylor; Cathy L Bell-Horner; Michael J Forster; Glenn H Dillon
Journal:  J Pharmacol Exp Ther       Date:  2009-02-24       Impact factor: 4.030

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.